Diabetes mellitus type 2 Flashcards
Define T2DM
Characterised by increased peripheral resistance to insulin action, impaired insulin secretion & increased hepatic glucose output
Aetiology of T2DM
4
- Genetic & environmental
- Few monogenic causes of diabetes ( e.g MODY, mitochondrial diabetes)
- Obesity increases risk (due to action of adipocytokines)
Can occur secondary to
- pancreatic disease (e.g chronic pancreatitis)
- endocrine disease (e.g Cushing’s, acromegaly, phaechromocytoma, glucagonoma)
- drugs (e.g corticosteroids, atypical antipsychotics, protease inhibitors)
Epidemiology of T2DM
Uk, ethnicities, link
5-10% prevalence in UK
Asians, africans & hispanics at greater risk
incidence increased in past 20 yrs linked to increasing prevalence of obesity
Presenting symptoms of T2DM
7
- may be incidental finding
- polydipsia
- polyuria
- tiredness
- may present with hyperosmolar hyperglycaemic state (HHS)
- infections (e.g infected foot ulcers, candidiasis, balanitis)
- assess cardiovascular risk factors: hypertension, hyperlipidaemia & smoking
Signs of T2DM on physical examination
5
Calculate BMI Waist circumference Blood pressure Diabetic foot (ischaemic & neuropathic signs) Skin changes (rare)
Investigations for T2DM - diagnosis
3
1 or more:
- symptoms of diabetes & random plasma glucose >11.1mmol/L
- fasting plasma glucose >7mmol/L
- 2 hr plasma glucose >11.1mmol/L after 75g oral glucose tolerance test
Investigations for T2DM - monitor
5
HbA1c U&Es lipid profile eGFR urine albumin: creatinine ratio (look for microalbuminuria)
Management of T2DM - glycaemic control
4
1) at diagnosis: lifestyle + metformin
2)
if HbA1c >7% after 3 months: lifestyle + metformin + sulphonylurea or basal insulin
3) if HbA1c >7% after 3 months: lifestyle + metformin + basal insulin
4) if HbA1c >7% after 3 months & fasting blood glucose >7mmol/L: add primal rapid acting insulin
(sulphonylurea may be given as a monotherapy if patients cannot tolerate metformin)
(pioglitazone (thiazolidinedione) may also be given alongside metformin & a sulphonylurea)
Prognosis for T2DM
general + 4 pre diabetes
Good prognosis w/ good control
Pre-diabetes diagnosed based on fasting blood glucose & oral glucose tolerance test:
- impaired fasting glucose (IFG): 5.6-6.9mmol/L
- impaired glucose tolerance (IGT): plasma glucose 7.8-11.0mmol/L measured 2 hrs after 75g oral glucose tolerance test
IFG or IGT => high risk of developing T2DM
Signs of diabetic foot
6
- dry skin
- reduced subcutaneous tissue
- ulceration
- gangrene
- Charcot’s arthropathy
- weak foot pulses
Skin changes in T2DM
3
Necrobiosis lipoidica diabeticorum - well demarcated plaques on shins/arms w/ shiny atrophic surface & red brown edges
Granuloma annulare - flesh coloured papules coalescing in rings on back of hands & fingers
Diabetic dermopathy - depressed pigmented scars on shins
Investigations for T2DM
2 group
Diagnosis
Monitoring
Management of T2DM
4 groups
Glycaemic control
Screening for complications
Pregnancy
HHS
Management of T2DM - screening for complications
5
Retinopathy Nephropathy Vascular disease Diabetic foot Cardiovascular risk factors (e.g. BP, cholesterol)
Management of T2DM - pregnancy
Requires strict glycaemic control & planning